HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

NRXS

NeurAxis, Inc. (AMEX)

Healthcare — Biotechnology

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

None 2 analysts
$7.08
$-0.23 (-3.15%)
Target: $11.00 (55.4%)
Sign in to add NRXS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$87.68M
P/E Ratio (TTM)-
Forward P/E-118.00
EPS (TTM)$-0.80
Dividend Yield-
Profit Margin-170.11%
Revenue Growth79.50%
ROE-242.53%
Debt/Equity6.15
Recommendation None
Analyst Target$11.00
Analysts2
Indexes AMEX

Technical Indicators

RSI (14)56.1
Beta1.41
SMA 20-
SMA 40-
52-Week High$9.33
52-Week Low$2.20
50-Day Avg$7.43
200-Day Avg$5.11
Avg Volume152.1K
Volume88.0K

Performance Analysis

BULLISH

NRXS shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 68% of its 52-week range.
+ RSI at 56.1 shows positive momentum.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
+ Strong revenue growth of 79.5% year-over-year.
- Operating at a loss with -170.1% margin.
~ Wall Street consensus is "none" from 2 analysts.
+ Average analyst target of $11.00 implies 55.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:23 UTC

Back to Screener Export Report